Literature DB >> 9211076

Primary prevention of coronary heart disease. What has WOSCOPS told us and what questions remain? West Of Scotland Coronary Prevention Study.

V Maher1, J Sinfuego, P Chao, J Parekh.   

Abstract

Coronary heart disease remains the major cause of death and morbidity in developed countries. As a consequence, its prevention constitutes a significant public health challenge. In recent times, our understanding of this disease process has expanded and many of the factors that influence its expression have been elucidated. In addition, a number of trials of diet and lipid-lowering drugs have been performed in an effort to tackle this problem. These studies demonstrate that when lipid levels are favourably altered, cardiovascular events are reduced without adverse effect. The rate at which event outcomes diverge between treated and untreated patients depends on the degree of atherosclerosis manifestation prior to treatment and the aggressiveness of the lipid altering strategy. Nonetheless, to date, the residual risk of cardiovascular events is still unacceptably high despite even the most potent lipid-lowering treatments used in these trials. In order to minimise the risk of future events, earlier intervention and a greater change in LDL and HDL cholesterol levels are needed in conjunction with other risk factor modifications.

Entities:  

Mesh:

Year:  1997        PMID: 9211076     DOI: 10.2165/00003495-199754010-00001

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  33 in total

1.  Should there be a moratorium on the use of cholesterol lowering drugs?

Authors:  G Davey Smith; J Pekkanen
Journal:  BMJ       Date:  1992-02-15

Review 2.  The response-to-retention hypothesis of early atherogenesis.

Authors:  K J Williams; I Tabas
Journal:  Arterioscler Thromb Vasc Biol       Date:  1995-05       Impact factor: 8.311

3.  Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)

Authors: 
Journal:  JAMA       Date:  1993-06-16       Impact factor: 56.272

Review 4.  Plaque fissuring--the cause of acute myocardial infarction, sudden ischaemic death, and crescendo angina.

Authors:  M J Davies; A C Thomas
Journal:  Br Heart J       Date:  1985-04

5.  Multifactorial trial in the prevention of coronary heart disease: 3. Incidence and mortality results.

Authors: 
Journal:  Eur Heart J       Date:  1983-03       Impact factor: 29.983

6.  Physicochemical and histological changes in the arterial wall of nonhuman primates during progression and regression of atherosclerosis.

Authors:  D M Small; M G Bond; D Waugh; M Prack; J K Sawyer
Journal:  J Clin Invest       Date:  1984-06       Impact factor: 14.808

7.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.

Authors:  F M Sacks; M A Pfeffer; L A Moye; J L Rouleau; J D Rutherford; T G Cole; L Brown; J W Warnica; J M Arnold; C C Wun; B R Davis; E Braunwald
Journal:  N Engl J Med       Date:  1996-10-03       Impact factor: 91.245

8.  Triggering of acute myocardial infarction by heavy physical exertion. Protection against triggering by regular exertion. Determinants of Myocardial Infarction Onset Study Investigators.

Authors:  M A Mittleman; M Maclure; G H Tofler; J B Sherwood; R J Goldberg; J E Muller
Journal:  N Engl J Med       Date:  1993-12-02       Impact factor: 91.245

9.  Combined effects of HDL cholesterol, triglyceride, and total cholesterol concentrations on 18-year risk of atherosclerotic disease.

Authors:  C M Burchfiel; A Laws; R Benfante; R J Goldberg; L J Hwang; D Chiu; B L Rodriguez; J D Curb; D S Sharp
Journal:  Circulation       Date:  1995-09-15       Impact factor: 29.690

10.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.

Authors:  J Shepherd; S M Cobbe; I Ford; C G Isles; A R Lorimer; P W MacFarlane; J H McKillop; C J Packard
Journal:  N Engl J Med       Date:  1995-11-16       Impact factor: 91.245

View more
  3 in total

1.  Liver phospholipid transfer protein (PLTP) expression with a PLTP-null background promotes very low-density lipoprotein production in mice.

Authors:  Amirfarbod Yazdanyar; Xian-Cheng Jiang
Journal:  Hepatology       Date:  2012-06-11       Impact factor: 17.425

Review 2.  HMG-CoA reductase inhibitors and myotoxicity.

Authors:  M Ucar; T Mjörndal; R Dahlqvist
Journal:  Drug Saf       Date:  2000-06       Impact factor: 5.606

3.  Pharmacologic inhibition of sphingomyelin synthase (SMS) activity reduces apolipoprotein-B secretion from hepatocytes and attenuates endotoxin-mediated macrophage inflammation.

Authors:  Bin Lou; Jibin Dong; Yali Li; Tingbo Ding; Tingting Bi; Yue Li; Xiaodong Deng; Deyong Ye; Xian-Cheng Jiang
Journal:  PLoS One       Date:  2014-07-17       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.